Please assess the completion status of the following clinical trial:

Trial Title: Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Clinical Inclusion Criteria:~1. Male or non-pregnant female ≥18 years of age;~2. Rutherford Clinical Category 2-4;~3. Patient is willing to provide informed consent, is geographically stable and comply with the required follow up visits, testing schedule and medication regimen;~   Angiographic Lesion Inclusion Criteria:~4. Length ≤15 cm;~5. Up to two focal lesions or segments within the designated 15 cm length of vessel may be treated (e.g. two discrete segments, separated by several cm, but both falling within a composite length of ≤15 cm);~6. ≥70% stenosis by visual estimate;~7. Lesion location starts ≥1 cm below the common femoral bifurcation and terminates distally ≤2 cm below the tibial plateau AND ≥1 cm above the origin of the TP trunk;~8. de novo lesion(s) or non-stented restenotic lesion(s) \>90 days from prior angioplasty procedure;~9. Lesion is located at least 3 cm from any stent, if target vessel was previously stented;~10. Target vessel diameter between ≥4 and ≤6 mm and able to be treated with available device size matrix;~11. Successful, uncomplicated (without use of a crossing device) antegrade wire crossing of lesion;~12. A patent inflow artery free from significant lesion (≥50% stenosis) as confirmed by angiography (treatment of target lesion acceptable after successful treatment of inflow artery lesions); NOTE: Successful inflow artery treatment is defined as attainment of residual diameter stenosis ≤30% without death or major vascular complication.~13. At least one patent native outflow artery to the ankle, free from significant (≥50%) stenosis as confirmed by angiography that has not previously been revascularized (treatment of outflow disease is NOT permitted during the index procedure);~14. Contralateral limb lesion(s) cannot be treated within 2 weeks before and/or planned 30 days after the protocol treatment in order to avoid confounding complications;~15. No other prior vascular interventions within 2 weeks before and/or planned 30 days after the protocol treatment.~Exclusion Criteria:~Patients will be excluded if ANY of the following conditions apply:~1. Pregnant or planning on becoming pregnant or men intending to father children;~2. Life expectancy of \<5 years;~3. Patient is currently participating in an investigational drug or other device study or previously enrolled in this study; NOTE: Enrollment in another clinical trial during the follow up period is not allowed.~4. History of hemorrhagic stroke within 3 months;~5. Previous or planned surgical or interventional procedure within 2 weeks before or within 30 days after the index procedure;~6. History of myocardial infarction (MI), thrombolysis or angina within 2 weeks of enrollment;~7. Rutherford Class 0, 1, 5 or 6;~8. Renal failure or chronic kidney disease with modification in diet in renal disease glomerular filtration rate (MDRD GFR) ≤30 ml/min per 1.73 m2 (or serum creatinine ≥2.5 mg/L within 30 days of index procedure or treated with dialysis);~9. Prior vascular surgery of the index limb, with the exception of remote common femoral patch angioplasty separated by at least 2 cm from the target lesion;~10. Inability to take required study medications or allergy to contrast that cannot be adequately managed with pre- and post-procedure medication;~11. Anticipated use of IIb/IIIa inhibitor prior to randomization;~12. Ipsilateral retrograde access;~13. Composite lesion length is \>15 cm or there is no normal proximal arterial segment in which duplex flow velocity can be measured;~14. Significant inflow disease. Successful treatment of inflow disease allowed prior to target lesion treatment;~15. Known inadequate distal outflow (\>50 % stenosis of distal popliteal and/or all three tibial vessels), or planned future treatment of vascular disease distal to the target lesion;~16. Sudden symptom onset, acute vessel occlusion, or acute or sub-acute thrombus in target vessel;~17. Severe calcification that renders the lesion un-dilatable;~18. Use of adjunctive treatment modalities (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, etc.).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Moxy Drug Coated Balloon (Type: EXPERIMENTAL): Paclitaxel coated balloon catheter
- Standard Uncoated Angioplasty Balloon (Type: ACTIVE_COMPARATOR): PTA Catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).